IASLC WCLC 2019: Safety of Nivolumab Plus Ipilimumab Confirmed in Special Populations with Non-Small Cell Lung Cancer
Poorer performance status and comorbidities did not increase adverse event burden
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.